Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he made of the difference in uptake rates between maternal and infant RSV immunisations when developing the national immunisation programme.

The policy for the respiratory syncytial virus (RSV) programme is based on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), an independent expert advisory committee. The JCVI considered RSV modelling that included different levels of uptake for maternal or infant immunisation. The JCVI advised that either antenatal maternal vaccination or infant monoclonal antibody immunisation strategies could be suitable for a universal United Kingdom programme and did not have a preference. Maternal vaccination became the UK programme from September 2024 following a competitive tender.

The JCVI had noted that protection of preterm infants would need to be looked at if the UK adopted a maternal vaccination programme. At the October 2024 meeting the JCVI advised that a programme to extend a potential offer of nirsevimab, a monoclonal antibody, to very and extremely premature infants could be cost effective.

Based on JCVI’s advice, the RSV selective immunisation programme for high-risk infants switched in September 2025 from using palivizumab to using nirsevimab, and was extended to include premature babies born at less than 32 weeks gestation.